JP2017524372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524372A5 JP2017524372A5 JP2017515021A JP2017515021A JP2017524372A5 JP 2017524372 A5 JP2017524372 A5 JP 2017524372A5 JP 2017515021 A JP2017515021 A JP 2017515021A JP 2017515021 A JP2017515021 A JP 2017515021A JP 2017524372 A5 JP2017524372 A5 JP 2017524372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- nos
- isolated
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004335P | 2014-05-29 | 2014-05-29 | |
| US62/004,335 | 2014-05-29 | ||
| PCT/US2015/033129 WO2015184228A1 (en) | 2014-05-29 | 2015-05-29 | Anti-human papillomavirus 16 e7 t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127833A Division JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524372A JP2017524372A (ja) | 2017-08-31 |
| JP2017524372A5 true JP2017524372A5 (enExample) | 2018-06-28 |
| JP6742991B2 JP6742991B2 (ja) | 2020-08-19 |
Family
ID=53396593
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515021A Active JP6742991B2 (ja) | 2014-05-29 | 2015-05-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2020127833A Active JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2021203953A Active JP7291196B2 (ja) | 2014-05-29 | 2021-12-16 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2023091878A Active JP7535158B2 (ja) | 2014-05-29 | 2023-06-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2024126652A Active JP7744479B2 (ja) | 2014-05-29 | 2024-08-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127833A Active JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2021203953A Active JP7291196B2 (ja) | 2014-05-29 | 2021-12-16 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2023091878A Active JP7535158B2 (ja) | 2014-05-29 | 2023-06-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2024126652A Active JP7744479B2 (ja) | 2014-05-29 | 2024-08-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10174098B2 (enExample) |
| EP (3) | EP3149031B1 (enExample) |
| JP (5) | JP6742991B2 (enExample) |
| KR (2) | KR102618267B1 (enExample) |
| CN (2) | CN113150112B (enExample) |
| AU (5) | AU2015266818B2 (enExample) |
| CA (1) | CA2950192A1 (enExample) |
| CY (1) | CY1122790T1 (enExample) |
| DK (1) | DK3149031T3 (enExample) |
| ES (1) | ES2784237T3 (enExample) |
| HR (1) | HRP20200376T1 (enExample) |
| IL (3) | IL290655B2 (enExample) |
| LT (1) | LT3149031T (enExample) |
| MX (2) | MX375379B (enExample) |
| PL (1) | PL3149031T3 (enExample) |
| PT (1) | PT3149031T (enExample) |
| SA (1) | SA516380394B1 (enExample) |
| SI (1) | SI3149031T1 (enExample) |
| SM (1) | SMT202000143T1 (enExample) |
| WO (1) | WO2015184228A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3149031T (pt) | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| US10544392B2 (en) | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| MX2018006789A (es) | 2015-12-03 | 2019-02-13 | Juno Therapeutics Inc | Receptores quimericos modificados y composiciones y metodos relacionados. |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| KR20190062505A (ko) | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| AU2018269194B2 (en) * | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| IL299348B2 (en) | 2017-06-28 | 2025-05-01 | Regeneron Pharma | Antigen-binding proteins against human papillomavirus and methods of using them |
| DK3688032T3 (da) | 2017-09-26 | 2025-12-15 | Cero Therapeutics Holdings Inc | Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder |
| IL273515B2 (en) | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| US12227554B2 (en) * | 2017-10-05 | 2025-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| JP2021502077A (ja) | 2017-11-06 | 2021-01-28 | エディタス・メディシン，インコーポレイテッド | 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| ES3052818T3 (en) | 2018-02-09 | 2026-01-14 | Us Health | Tethered interleukin-15 and interleukin-21 |
| RU2020135107A (ru) | 2018-03-28 | 2022-04-29 | Серо Терапьютикс, Инк. | Клеточные иммунотерапевтические композиции и их применения |
| MX2020010235A (es) | 2018-03-28 | 2020-10-28 | Cero Therapeutics Inc | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. |
| US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| CN112585277A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| CN112262212B (zh) | 2018-04-24 | 2024-07-12 | 美国卫生和人力服务部 | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 |
| US20210155941A1 (en) * | 2018-06-22 | 2021-05-27 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN113811329B (zh) | 2019-04-19 | 2025-10-14 | 天科雅生物科技有限公司 | 抗pd-1抗体和其用途 |
| CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| CN114245745A (zh) * | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
| WO2020264269A1 (en) | 2019-06-27 | 2020-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| CN110357952B (zh) * | 2019-07-17 | 2022-03-22 | 深圳市因诺转化医学研究院 | 识别人乳头瘤病毒hpv16-e7抗原的tcr |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| EP4086281A4 (en) * | 2019-12-30 | 2024-02-14 | China Immunotech (Beijing) Biotechnology Co., Ltd | IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN113072635B (zh) * | 2020-01-06 | 2023-08-25 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv抗原的t细胞受体及其编码序列 |
| JP7645500B2 (ja) * | 2020-05-07 | 2025-03-14 | ブリスター イムノテック リミテッド | 改善されたｔ細胞受容体共刺激分子キメラ |
| EP4159768A4 (en) * | 2020-05-25 | 2024-11-20 | Bristar Immunotech Limited | Enhanced synthetic t-cell receptor and antigen receptor |
| WO2021252517A1 (en) * | 2020-06-09 | 2021-12-16 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| JP7868033B2 (ja) | 2020-08-14 | 2026-06-01 | セロ・セラピューティクス・ホールディングス・インコーポレイテッド | キメラｔｉｍ受容体およびその使用 |
| AU2021336399A1 (en) | 2020-09-04 | 2023-05-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r273c or y220c mutations in p53 |
| WO2022060904A1 (en) * | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| EP4334340A1 (en) | 2021-05-07 | 2024-03-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| WO2023274382A1 (zh) * | 2021-06-30 | 2023-01-05 | 华夏英泰（北京）生物技术有限公司 | 一种多靶点合成t细胞受体抗原/抗体受体及其应用 |
| WO2023036169A1 (en) * | 2021-09-07 | 2023-03-16 | Corregene Biotechnology Co., Ltd. | Antigen binding proteins and uses thereof |
| CN118265721A (zh) * | 2021-10-18 | 2024-06-28 | 得克萨斯州大学系统董事会 | 靶向ndc80抗原的肽和经改造t细胞受体及使用方法 |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| WO2023086477A2 (en) * | 2021-11-10 | 2023-05-19 | Tscan Therapeutics, Inc. | Binding proteins recognizing hpv16 e7 antigen and uses thereof |
| EP4463549A2 (en) | 2022-01-14 | 2024-11-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| US20250243260A1 (en) | 2022-03-07 | 2025-07-31 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| CN117402233A (zh) * | 2022-05-10 | 2024-01-16 | 广州医科大学 | 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr |
| JP2025531268A (ja) | 2022-09-19 | 2025-09-19 | チューン セラピューティクス インコーポレイテッド | Ｔ細胞機能を調節するための組成物、システム、および方法 |
| CN116731155B (zh) * | 2022-09-21 | 2024-03-22 | 新景智源生物科技(苏州)有限公司 | 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途 |
| AU2024241888A1 (en) | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| EP4754248A1 (en) | 2023-07-31 | 2026-06-10 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| WO2025096419A1 (en) * | 2023-10-31 | 2025-05-08 | Lyell Immunopharma, Inc. | T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof |
| AU2025212850A1 (en) | 2024-01-26 | 2026-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025193926A1 (en) | 2024-03-15 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting e545k or n345k mutation in pik3ca |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| CN105461802A (zh) * | 2005-04-01 | 2016-04-06 | 英美偌科有限公司 | 高亲和力hiv t细胞受体 |
| US20090304657A1 (en) | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP2468763B1 (en) | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CN110511960B (zh) | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| PT3149031T (pt) * | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
-
2015
- 2015-05-29 PT PT157290040T patent/PT3149031T/pt unknown
- 2015-05-29 AU AU2015266818A patent/AU2015266818B2/en active Active
- 2015-05-29 IL IL290655A patent/IL290655B2/en unknown
- 2015-05-29 KR KR1020227032043A patent/KR102618267B1/ko active Active
- 2015-05-29 US US15/313,673 patent/US10174098B2/en active Active
- 2015-05-29 DK DK15729004.0T patent/DK3149031T3/da active
- 2015-05-29 EP EP15729004.0A patent/EP3149031B1/en active Active
- 2015-05-29 CA CA2950192A patent/CA2950192A1/en active Pending
- 2015-05-29 EP EP19217074.4A patent/EP3689900B1/en active Active
- 2015-05-29 WO PCT/US2015/033129 patent/WO2015184228A1/en not_active Ceased
- 2015-05-29 CN CN202110399056.9A patent/CN113150112B/zh active Active
- 2015-05-29 ES ES15729004T patent/ES2784237T3/es active Active
- 2015-05-29 KR KR1020167033189A patent/KR102445667B1/ko active Active
- 2015-05-29 CN CN201580031789.XA patent/CN106661098B/zh active Active
- 2015-05-29 JP JP2017515021A patent/JP6742991B2/ja active Active
- 2015-05-29 HR HRP20200376TT patent/HRP20200376T1/hr unknown
- 2015-05-29 SM SM20200143T patent/SMT202000143T1/it unknown
- 2015-05-29 EP EP25187143.0A patent/EP4609876A3/en active Pending
- 2015-05-29 MX MX2016015383A patent/MX375379B/es active IP Right Grant
- 2015-05-29 LT LTEP15729004.0T patent/LT3149031T/lt unknown
- 2015-05-29 PL PL15729004T patent/PL3149031T3/pl unknown
- 2015-05-29 SI SI201531126T patent/SI3149031T1/sl unknown
-
2016
- 2016-11-07 IL IL248797A patent/IL248797B/en active IP Right Grant
- 2016-11-24 MX MX2020010035A patent/MX2020010035A/es unknown
- 2016-11-29 SA SA516380394A patent/SA516380394B1/ar unknown
-
2018
- 2018-11-30 US US16/205,631 patent/US10870687B2/en active Active
-
2019
- 2019-12-18 AU AU2019283892A patent/AU2019283892B2/en active Active
-
2020
- 2020-03-16 CY CY20201100238T patent/CY1122790T1/el unknown
- 2020-07-29 JP JP2020127833A patent/JP6997267B2/ja active Active
- 2020-11-23 US US17/101,360 patent/US11434272B2/en active Active
-
2021
- 2021-04-13 AU AU2021202227A patent/AU2021202227B2/en active Active
- 2021-04-21 IL IL282518A patent/IL282518B/en unknown
- 2021-12-16 JP JP2021203953A patent/JP7291196B2/ja active Active
-
2022
- 2022-08-01 US US17/816,496 patent/US12534508B2/en active Active
-
2023
- 2023-02-06 AU AU2023200608A patent/AU2023200608B2/en active Active
- 2023-06-02 JP JP2023091878A patent/JP7535158B2/ja active Active
-
2024
- 2024-08-02 JP JP2024126652A patent/JP7744479B2/ja active Active
- 2024-11-19 AU AU2024266702A patent/AU2024266702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527230A5 (enExample) | ||
| Jee et al. | Immunology of HPV-mediated cervical cancer: current understanding | |
| Baldwin et al. | Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia | |
| Klencke et al. | Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101 | |
| Davidson et al. | Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) | |
| Day et al. | In vivo mechanisms of vaccine-induced protection against HPV infection | |
| HRP20200376T1 (hr) | Receptori t-stanica protiv ljudskog papiloma virusa 16e7 | |
| US12551546B2 (en) | Materials and methods relating to immunogenic epitopes from human papilloma virus | |
| Gao et al. | Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector | |
| Shimakage et al. | Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression | |
| Dhanushkodi et al. | Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+ CD44+ CD62L− CD8+ T Cells and Memory CCR10+ B220+ CD27+ B Cells into the Infected Vaginal Mucosa | |
| Vanajothi et al. | HPV-mediated cervical cancer: a systematic review on immunological basis, molecular biology, and immune evasion mechanisms | |
| Mattil-Fritz et al. | Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles | |
| Afshar Moghaddam et al. | Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview | |
| Visalli et al. | Identification of the Epstein Barr virus portal | |
| Mahmoudi et al. | Prostate cancer and human papillomavirus infection: a recent literature review | |
| CN101153059B (zh) | 用于鼻咽癌筛查、诊断和治疗效果预测的elisa试剂盒 | |
| Gao et al. | Identification and characterization of the duck enteritis virus (DEV) US2 gene | |
| Davies et al. | Definition of murine T helper cell determinants in the major capsid protein of human papillomavirus type 16 | |
| Sauter et al. | Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells | |
| Arregui et al. | Oncogenic human papillomaviruses: high-risk human papillomaviruses: towards a better understanding of the mechanisms of viral transformation, latency and immune-escape | |
| Yhee et al. | Characterization of canine oral papillomavirus by histopathological and genetic analysis in Korea | |
| Li et al. | Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway | |
| Passmore et al. | Host immune responses associated with clearance or persistence of human papillomavirus infections | |
| Li et al. | Cervical cancer screening and prevention |